Altered colonic mucosal availability of n-3 and n-6 polyunsaturated fatty acids in ulcerative colitis and the relationship to disease activity

Journal of Crohn's and Colitis

Volumn 8, Issue 1, 2014, Pages 70-79

  Pearl, Daniel S ^a   Masoodi, Mojgan ^b,c   Eiden, Michael ^b   Brümmer, Janine ^d   Gullick, Darren ^d   Mckeever, Tricia M ^e   Whittaker, Mark A ^a   Nitch Smith, Harriet ^a   Brown, James F ^d   Shute, Janis K ^d   Mills, Graham ^d   Calder, Philip C ^f   Trebble, Timothy M ^a  

^a PORTSMOUTH HOSPITALS NHS TRUST   (United Kingdom)

^b MRC HUMAN NUTRITION RESEARCH   (United Kingdom)

^c NESTLÉ RESEARCH CENTER   (Switzerland)

^d UNIVERSITY OF PORTSMOUTH   (United Kingdom)

^e UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^f UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

Arachidonic acid; Cytokine; Eicosanoid; Eicosapentaenoic acid; Inflammation

Indexed keywords

6 MERCAPTOPURINE DERIVATIVE; ARACHIDONIC ACID; CORTICOSTEROID DERIVATIVE; CYCLOSPORIN; DOCOSAHEXAENOIC ACID; DOCOSAPENTAENOIC ACID; ICOSANOID; ICOSAPENTAENOIC ACID; LINOLEIC ACID; LINOLENIC ACID; METHOTREXATE; OMEGA 3 FATTY ACID; OMEGA 6 FATTY ACID;

ADULT; ARTICLE; BIOAVAILABILITY; COLON BIOPSY; COLON MUCOSA; CONTROLLED STUDY; DISEASE ACTIVITY; FEMALE; FOOD FREQUENCY QUESTIONNAIRE; GAS CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; PRIORITY JOURNAL; PROSPECTIVE STUDY; ULCERATIVE COLITIS;

5-AMINOSALICYLIC ACID; 5-ASA; AA; ALPHA LINOLENIC ACID; ARACHIDONIC ACID; CYTOKINE; DHA; DOCOSAHEXAENOIC ACID; DOCOSAPENTAENOIC ACID; DPA; EI-SIM; EICOSANOID; EICOSAPENTAENOIC ACID; ELECTRON IMPACT SELECTIVE ION MONITORING; EPA; FA; FATTY ACID; GAS CHROMATOGRAPHY MASS SPECTROMETRY; GC/MS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HPLC; INFLAMMATION; LA; LC/MS; LEUKOTRIENES; LINOLEIC ACID; LIQUID CHROMATOGRAPHY MASS SPECTROMETRY; LT; PEROXISOME PROLIFERATOR ACTIVATOR RECEPTOR Γ; PG; POLYUNSATURATED FATTY ACID; PPARΓ; PROSTAGLANDINS; PUFA; SOLID PHASE EXTRACTION; SPE; UC; ULCERATIVE COLITIS; Α-LNA;

ADULT; BIOLOGICAL AVAILABILITY; CASE-CONTROL STUDIES; COLITIS, ULCERATIVE; COLON; DIET; ESTERIFICATION; FATTY ACIDS, OMEGA-3; FATTY ACIDS, OMEGA-6; FEMALE; HUMANS; INTESTINAL MUCOSA; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; QUESTIONNAIRES; SEVERITY OF ILLNESS INDEX;

EID: 84890116248     PISSN: 18739946     EISSN: 18764479     Source Type: Journal    
DOI: 10.1016/j.crohns.2013.03.013     Document Type: Article

References (40)

1. Stonnington C.M., Phillips S.F., Melton L.J., Zinsmeister A.R. Chronic ulcerative colitis: incidence and prevalence in a community. Gut 1987, 28:402-409.
2. Strober W., Fuss I., Mannon P. The fundamental basis of inflammatory bowel disease. J Clin Invest 2007, 117:514-521.
3. Geboes J.K. Histopathology of Crohn's disease and ulcerative colitis. Inflammatory bowel disease 2003, 255-276. Churchill Livingstone, Edinburgh, London, Melbourne. J. Satsangi, L.R. Sutherland, J.F. Colombel, C. Fiocci, R. Lofberg, J. Pemberton, P. Rutgeerts (Eds.).
4. Nielsen O.H., Elmgreen J. Activation of neutrophil chemotaxis by leukotriene B4 and 5-hydroxyeicosatetraenoic acid in chronic inflammatory bowel disease. Scand J Clin Lab Invest 1987, 47:605-611.
5. Palmblad J., Malmsten C.L., Uden A.M., Radmark O., Engstedt L., Samuelsson B. Leukotriene B4 is a potent and stereospecific stimulator of neutrophil chemotaxis and adherence. Blood 1981, 58:658-661.
6. Rampton D.S., Sladen G.E., Youlten L.J. Rectal mucosal prostaglandin E2 release and its relation to disease activity, electrical potential difference, and treatment in ulcerative colitis. Gut 1980, 21:591-596.
7. Sharon P., Stenson W.F. Enhanced synthesis of leukotriene B4 by colonic mucosa in inflammatory bowel disease. Gastroenterology 1984, 86:453-460.
8. Sutherland L., Roth D., Beck P., May G., Makiyama K. Oral 5-aminosalicylic acid for inducing remission in ulcerative colitis. Cochrane Database Syst Rev 2000, CD000543.
9. Marteau P., Probert C.S., Lindgren S., Gassul M., Tan T.G., Dignass A., et al. Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study. Gut 2005, 54:960-965.
10. Lee T.H., Sethi T., Crea A.E., Peters W., Arm J.P., Horton C.E., et al. Characterization of leukotriene B3: comparison of its biological activities with leukotriene B4 and leukotriene B5 in complement receptor enhancement, lysozyme release and chemotaxis of human neutrophils. Clin Sci (Lond) 1988, 74:467-475.
11. Needleman P., Raz A., Minkes M.S., Ferrendelli J.A., Sprecher H. Triene prostaglandins: prostacyclin and thromboxane biosynthesis and unique biological properties. Proc Natl Acad Sci U S A 1979, 76:944-948.
12. Calder P.C. Polyunsaturated fatty acids, inflammatory processes and inflammatory bowel diseases. Mol Nutr Food Res 2008, 52:885-897.
13. Wilton D.C. Phospholipases. Biochemistry of lipids, lipoproteins and membranes, 5th edition 2008, 305-330. Elsevier, Amsterdam, Boston, Heidelberg, London, New York, Oxford, Paris, San Diego, San Francisco, Singapore, Sydney, Tokyo. First ed. D.E. Vance, J.E. Vance (Eds.).
14. Lands W.E. Biochemistry and physiology of n-3 fatty acids. FASEB J 1992, 6:2530-2536.
15. Smith W.L., Murphy R.C. The eicosanoids: cyclooxygenases, lipoxygenase, and epoxygenase pathways. Biocehmistry of lipids, lipoproteins and membranes, 5th edition 2008, 331-362. Elsevier, Amsterdam, Boston, Heidelberg, London, New York, Oxford, Paris, San Diego, San Francisco, Singapore, Sydney, Tokyo. 1 ed. D.E. Vance, J.E. Vance (Eds.).
16. Wada M., DeLong C.J., Hong Y.H., Rieke C.J., Song I., Sidhu R.S., et al. Enzymes and receptors of prostaglandin pathways with arachidonic acid-derived versus eicosapentaenoic acid-derived substrates and products. J Biol Chem 2007, 282:22254-22266.
17. Gomes P., du B.C., Smith C.L., Holdstock G. Relationship between disease activity indices and colonoscopic findings in patients with colonic inflammatory bowel disease. Gut 1986, 27:92-95.
18. D'Haens G., Sandborn W.J., Feagan B.G., Geboes K., Hanauer S.B., Irvine E.J., et al. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology 2007, 132:763-786.
19. Sutherland L.R., Martin F., Greer S., Robinson M., Greenberger N., Saibil F., et al. 5-Aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis. Gastroenterology 1987, 92:1894-1898.
20. Dill A.L., Eberlin L.S., Costa A.B., Ifa D.R., Cooks R.G. Data quality in tissue analysis using desorption electrospray ionization. Anal Bioanal Chem 2011, 401:1949-1961.
21. Broadfield E., McKeever T., Fogarty A., Britton J. Measuring dietary fatty acid intake:validation of a food-frequency questionnaire against 7 d weighed records. Br J Nutr 2003, 90:215-220.
22. Dodds E.D., McCoy M.R., Rea L.D., Kennish J.M. Gas chromatographic quantification of fatty acid methyl esters: flame ionization detection vs. electron impact mass spectrometry. Lipids 2005, 40:419-428.
23. Masoodi M., Eiden M., Koulman A., Spaner D., Volmer D.A. Comprehensive lipidomics analysis of bioactive lipids in complex regulatory networks. Anal Chem 2010, 82:8176-8185.
24. Trebble T.M., Arden N.K., Wootton S.A., Mullee M.A., Calder P.C., Burdge G.C., et al. Peripheral blood mononuclear cell fatty acid composition and inflammatory mediator production in adult Crohn's disease. Clin Nutr 2004, 23:647-655.
25. Whelan J., Li B., Birdwell C. Dietary arachidonic acid increases eicosanoid production in the presence of equal amounts of dietary eicosapentaenoic acid. Adv Exp Med Biol 1997, 400B:897-904.
26. Almallah Y.Z., Ewen S.W., El-Tahir A., Mowat N.A., Brunt P.W., Sinclair T.S., et al. Distal proctocolitis and n-3 polyunsaturated fatty acids (n-3 PUFAs): the mucosal effect in situ. J Clin Immunol 2000, 20:68-76.
27. Almallah Y.Z., El-Tahir A., Heys S.D., Richardson S., Eremin O. Distal procto-colitis and n-3 polyunsaturated fatty acids: the mechanism(s) of natural cytotoxicity inhibition. Eur J Clin Invest 2000, 30:58-65.
28. Bartram H.P., Gostner A., Scheppach W., Reddy B.S., Rao C.V., Dusel G., et al. Effects of fish oil on rectal cell proliferation, mucosal fatty acids, and prostaglandin E2 release in healthy subjects. Gastroenterology 1993, 105:1317-1322.
29. Bjorkkjaer T., Brun J.G., Valen M., Arslan G., Lind R., Brunborg L.A., et al. Short-term duodenal seal oil administration normalised n-6 to n-3 fatty acid ratio in rectal mucosa and ameliorated bodily pain in patients with inflammatory bowel disease. Lipids Health Dis 2006, 5:6.
30. Endres S., Ghorbani R., Kelley V.E., Georgilis K., Lonnemann G., van der Meer J.W., et al. The effect of dietary supplementation with n-3 polyunsaturated fatty acids on the synthesis of interleukin-1 and tumor necrosis factor by mononuclear cells. N Engl J Med 1989, 320:265-271.
31. Hillier K., Jewell R., Dorrell L., Smith C.L. Incorporation of fatty acids from fish oil and olive oil into colonic mucosal lipids and effects upon eicosanoid synthesis in inflammatory bowel disease. Gut 1991, 32:1151-1155.
32. Lee T.H., Hoover R.L., Williams J.D., Sperling R.I., Ravalese J., Spur B.W., et al. Effect of dietary enrichment with eicosapentaenoic and docosahexaenoic acids on in vitro neutrophil and monocyte leukotriene generation and neutrophil function. N Engl J Med 1985, 312:1217-1224.
33. Trebble T.M., Arden N.K., Wootton S.A., Calder P.C., Mullee M.A., Fine D.R., et al. Fish oil and antioxidants alter the composition and function of circulating mononuclear cells in Crohn disease. Am J Clin Nutr 2004, 80:1137-1144.
34. Belluzzi A. N-3 fatty acids for the treatment of inflammatory bowel diseases. Proc Nutr Soc 2002, 61:391-395.
35. MacLean C.H., Mojica W.A., Morton S.C., Pencharz J., Hasenfeld G.R., Tu W., et al. Effects of omega-3 fatty acids on lipids and glycemic control in type II diabetes and the metabolic syndrome and on inflammatory bowel disease, rheumatoid arthritis, renal disease, systemic lupus erythematosus, and osteoporosis. Evid Rep Technol Assess (Summ) 2004, 1-4.
36. Stanke-Labesque F., Moliere P., Bessard J., Laville M., Vericel E., Lagarde M. Effect of dietary supplementation with increasing doses of docosahexaenoic acid on neutrophil lipid composition and leukotriene production in human healthy volunteers. Br J Nutr 2008, 100:829-833.
37. Vong L., Ferraz J.G., Panaccione R., Beck P.L., Wallace J.L. A pro-resolution mediator, prostaglandin D(2), is specifically up-regulated in individuals in long-term remission from ulcerative colitis. Proc Natl Acad Sci U S A 2010, 107:12023-12027.
38. Ananthakrishnan A.N., Higuchi L.M., Huang E.S., Khalili H., Richter J.M., Fuchs C.S., et al. Aspirin, nonsteroidal anti-inflammatory drug use, and risk for Crohn disease and ulcerative colitis: a cohort study. Ann Intern Med 2012, 156:350-359.
39. Sharon P., Ligumsky M., Rachmilewitz D., Zor U. Role of prostaglandins in ulcerative colitis. Enhanced production during active disease and inhibition by sulfasalazine. Gastroenterology 1978, 75:638-640.
40. Iacucci M., de S.S., Ghosh S. Mesalazine in inflammatory bowel disease: a trendy topic once again?. Can J Gastroenterol 2010, 24:127-133.